Genelux Corporation (GNLX) Stock Score, Valuation & Financial Research
Genelux Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 14/100.
Quick answer for GNLX
Genelux Corporation currently has a Wall Street Score of 14/100. The stored market price is $2.54. Its financial score is 4/100. Its valuation score is 0/100. The latest WSS change is -0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What Genelux Corporation does
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
GNLX financial snapshot
- Wall Street Score:
- 14/100
- Current price:
- $2.54
- Market capitalization:
- $113.9M
- Revenue:
- $8K
- Net income:
- $-33.8M
- Free cash flow:
- $-26.4M
- Cash:
- $9.2M
- Total debt:
- $2.4M
- EPS:
- -0.86
- Financial score:
- 4/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-26.4M, showing cash burn in the current stored period.
- The balance sheet shows $9.2M of cash versus $2.4M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.2 points: GNLX decreased 0.2 points because Asset declined by 2.1 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 4/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GNLX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.